United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate injection, usp, may be given parenterally as a pre-anesthetic medication in surgical patients to reduce salivation and bronchial secretions. it may also be used to suppress vagal activity associated with the use of halogenated hydrocarbons during inhalation anesthesia and reflex excitation arising from mechanical stimulation during surgery. the antispasmodic action of atropine is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. for ureteral and biliary colic, atropine concomitantly with morphine may be indicated. atropine relaxes the upper gi tract and colon during hypotonic radiography. in poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare nerve gases, large doses of atropine relieve the muscarine-like symptoms and some of the central nervous system manifestations. it is also used as an antidote for mushroom poisoning due to muscarine in certain species such as amanita muscaria. atropine sulfate

Israel - English - Ministry of Health

raz pharmaceutics ltd, israel - atropine sulfate - solution for injection - atropine sulfate 1 mg / 1 ml - atropine - preanesthetic medication to decrease excessive salivation and secretions of the respiratory tract. treatment of sinus bradycardia, particularly if complicated by hypotension.antidote in poisoning by organophosphorus.

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus, carbamate, or muscarinic mushroom poisoning, and to treat symptomatic bradycardia. none. risk summary limited available data with atropine sulfate injection use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes (see data) . there are risks to the mother and fetus associated with untreated severe or life-threatening muscarinic events (see clinical considerations) . animal reproduction studies have not been conducted with atropine sulfate injection. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 t

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus, carbamate, or muscarinic mushroom poisoning, and to treat symptomatic bradycardia. none. 8.1 pregnancy risk summary the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk severe or life-threatening muscarinic events such as acute organophosphate poisoning and symptomatic bradycardia are medical emergencies in pregnancy which can be fatal if left untreated. life-sustaining therapy for the pregnant woman should not be withheld due to potential concerns regarding the effects of atropine on the fetus. data human data no adequate and well-controlled studies are available regarding use of atropine in pregnant women. in a cohort study of 401 pregnancies in the first trimester and 797 pregnancies in the second or third trimester, atropine use was not associated with an increased risk of congenital malformation. in a surveillance study, 381 newborns were exposed to atropine during the first trimester; 18 major birth defects were observed when 16 were expected. no specific pattern of major birth defects was identified. in another surveillance study of 50 pregnancies in the first trimester, atropine use was not associated with an increased risk of malformations. methodological limitations of these observational studies including the inability to control for the dosage and timing of atropine exposure, underlying maternal disease, or concomitant maternal drug use, cannot definitively establish or exclude any drug- associated risk during pregnancy. 8.2 lactation risk summary trace amounts of atropine have been reported in human milk after oral intake. there are no available data on atropine levels in human milk after intravenous injection, the effects on the breastfed infant, or the effects on milk production. the lack of clinical data during lactation precludes a clear determination of the risk of atropine to an infant during lactation. clinical considerations minimizing exposure the elimination half-life of atropine is more than doubled in children less than 2 years of age [see clinical pharmacology (12.3)]. to minimize potential infant exposure to atropine sulfate injection, a woman may pump and discard her milk for 24 hours after use before resuming to breastfeed her infant. 8.5 geriatric use an evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate 1 mg in 1 ml - - in the treatment of parkinsonism. rigidity and tremor relieved by the apparently selective depressant action. - in the gastrointestinal tract to relieve pylorospasm, hypertonicity of the small intestine and the hypermotility of the colon. - to relieve hypertonicity of the uterine muscle. - to relax the spasm of biliary and uretered colic and bronchial spasm. - to diminish the tone of the detrusor muscle of the urinary bladder in the treatment of urinary tract disorders. - to control the crying and laughing episodes in patients with brain lesions. - in cases of closed head injuries which cause acetylcholine to be released or to be present in cerebrospinal fluid which in turn causes abnormal eeg patterns, stupor and neurological signs. - in the management of peptic ulcer. - in anesthesia to control excessive salivation and bronchial secretions. - to control rhinorrhea of acute rhinitis or hay fever. - as an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of aminata and

United States - English - NLM (National Library of Medicine)

sparhawk laboratories, inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate 15 mg in 1 ml - for use as an antidote in the treatment of organophosphate insecticide poisoning of cattle, horses and sheep.

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate 0.4 mg in 1 ml - 1. in the treatment of parkinsonism. rigidity and tremor relieved by the apparently selective depressant action. 2. in the gastrointestinal tract to relieve pylorospasm, hypertonicity of the small intestine and the hypermotility of the colon. 3. to relieve hypertonicity of the uterine muscle. 4. to relax the spasm of biliary and uretered colic and bronchial spasm. 5. to diminish the tone of the detrusor muscle of the urinary bladder in the treatment of urinary tract disorders. 6. to control the crying and laughing episodes in patients with brain lesions. 7. in cases of closed head injuries which cause acetylcholine to be released or to be present in cerebrospinal fluid which in turn causes abnormal eeg patterns, stupor and neurological signs. 8. in the management of peptic ulcer. 9. in anesthesia to control excessive salivation and bronchial secretions. 10. to control rhinorrhea of acute rhinitis or hay fever. 11. as an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain

United States - English - NLM (National Library of Medicine)

cardinal health - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate 0.4 mg in 1 ml

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - atropine sulfate - solution for injection in a pre-filled syringe - atropine sulfate 0.1 mg/ml - drugs for functional gastrointestinal disorders

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - atropine sulfate - solution for injection in a pre-filled syringe - atropine sulfate 0.1 mg/ml - drugs for functional gastrointestinal disorders